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Rheumatology key message 
 SSc patients can predict new digital ulcers and symptoms change during ulcer 
evolution and healing.






























































SIR, painful digital ulcers (DUs) are common in patients with systemic sclerosis (SSc) and often 
refractory to treatment (1,2). DUs are generally considered to be the result of tissue 
ischaemia, in particular, those which occur on the fingertips (2). Other  drivers of pathogenesis 
have been proposed for extensor DUs and for ulcers related to calcinosis cutis, although all 
SSc-DUs are considered to share an important (and potentially treatable) ischaemic aetiology 
(3–5). Little is known about the earliest ‘pre-clinical’ stage of DU evolution prior to the 
development of overt tissue damage or about how symptoms evolve during DU development 
and healing. The patient experience of SSc-DUs is highly complex and multi-faceted (6). We 
have recently reported a multicentre qualitative study that identified 5 major inter-related 
themes (and sub-themes) which characterise the patient experience of SSc-DUs: ‘Disabling 
pain and hypersensitivity’, ‘Deep and broad-ranging emotional impact’, ‘Impairment of 
physical and social activity’, ‘Factors aggravating occurrence, duration and impact’ and 
‘Mitigating, managing and adapting’ (7).  The aim of the present analysis was to understand 
patients’ perceptions and beliefs about DU pathogenesis (in order to provide novel insights 
for clinical practice and future clinical trial design), and to identify relevant domains for core 
outcome sets for SSc-DU assessment. 
Our methodological approach has been described previously [AC&R]. In brief, 29 patients with 
a confirmed diagnosis of SSc participated in 4 focus groups across the United Kingdom (Bath, 
Manchester and London) [7]. The study was approved by the East Midlands – Nottingham 1 
research Ethics Committee (REC reference – 18/EM/0018) and all participants provided 
written, informed consent. Patients had a broad spectrum of prior DU experiences: 1 previous 
DU (n=3), 2-4 previous DUs (n=9) and ≥5 previous DUs (n=17). The mean (SD) age of patients 
was 59.9 (13.3) years, two thirds of patients were female (n=20), and the majority had limited 
cutaneous SSc (n=20). The mean (SD) disease duration (defined as time from first non-
Raynaud’s phenomenon symptom) duration was 12.8 (9.7) years. The majority (n=27) of 
patients had ‘late’ disease which was defined as ≤3 years since their first non-Raynaud’s 
phenomenon symptom. The majority were receiving treatment with vasodilator medication 
for SSc-vasculopathy (including DU disease): calcium channel blockers (n=10), 
phosphodiesterase type-5 inhibitors (n=18) and endothelin receptor antagonists (n=9).






























































Focus groups were conducted using a bespoke topic guide and patients were recruited using 
a purposive sampling framework. Focus groups were audio recorded and anonymised 
transcripts were analysed using inductive thematic analysis (7). The present analysis reports 
patient perceptions and beliefs about DU pathogenesis and natural history. 
Three major themes emerged which encompassed patients’ perceptions and beliefs on DU 
pathogenesis. 
Theme 1 – Underlying causes of SSc-DUs: Most participants believed that there was a reason 
for an ulcer to develop rather than their occurrence being haphazard. Reasons included both 
‘external’ and ‘internal’ precipitating factors. ‘External’ causes included trauma, exposure to 
water, chemicals or infection, cold or change in temperature, and from cuts or skin splitting 
(Q1-3). ‘Internal’ causes were ‘poor circulation’ including from Raynaud’s phenomenon, 
calcinosis, and the residual effects (e.g. residual ischaemia) of previous ulcers rendering 
certain areas of the fingers susceptible to further ulceration (Q4-6).
Theme 2 – Symptoms prior to SSc-DU emergence: The majority of participants reported that 
they could recognise when an ulcer was about to emerge. The most common symptom was 
pain below the skin, often described as an internal pressure (Q7-8). Some participants also 
reported physical skin signs (e.g. a white patch with preserved overlying epithelialisation) 
which would subsequently break down/ulcerate (Q9-10).
Theme 3 – Patient experiences during DU evolution and healing: This was variable between 
participants. Surface characteristics ranged from being moist (including overt pus) to dry with 
a superficial crust, and occasionally with a central ‘core’ (Q11-14). Associated pain during 
ulcer healing also varied significantly between the participants.






























































Our data provide novel patient-perceived insights into the pathogenesis and natural history 
of SSc-DU. The emergence of SSc-DUs is not considered a random event and many patients 
have explanations for, and sometimes can anticipate development of new ulcers. These 
observations could be used to develop behavioural approaches to help prevent DU such as 
avoidance of severe cold, hand hygiene and avoidance of mechanical injury. The sites of 
previous DU may represent ischaemic foci, vulnerable to further ulceration and may guide 
local therapies such as botulinum toxin or topical nitrates as secondary prevention. To our 
knowledge, we are the first to describe a ‘pre-ulcer’ stage which could provide a ‘window of 
opportunity’ to intervene before the onset of overt tissue damage and ulceration. Relevant 
to clinical trial design, DU symptoms differ significantly at the time of SSc-DU emergence, and 
during DU evolution and healing, which has important implications for the development of 
patient-reported outcome instruments for assessing SSc-DUs.
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Table 1: Quotes supporting the themes which encompassed patients’ development and 
evolution. Quotes (Q) are sequentially cited in the text and are identified by subject 
(participant) number and location: Bath (B), Manchester (M) and London (L) 1&2 focus 
groups.
Theme Q Subject Quotation
Trauma 1 P3 M1: I just find it with a knock … I’ve had a lot of minor ones but only really one 
big one, but it’s always through trauma like touching something or, you 
know, if you just get your car keys and you catch it on a key or something
Chemicals 2 P4 B1: I also won’t touch work surfaces at work because they use chemicals on 
them, and it’s sticky, and that can really start my fingers off. So I don’t use 
anything…Very careful about anything in the house, but I found when I go 
to work, if I put my finger down and think oh, they’ve polished it, they 
never clean it, they just polish it and those sorts of things can irritate the 
skin and start… Yeah, you know you go somewhere and you don’t know if 
a chemical’s been used to soak or clean the surfaces, actually it’s 
something that starts them off
Cuts or skin 
splitting
3 P1 M1: it doesn’t appear for no reason, there’s usually a cut or a little where I’ve 
caught it somewhere, it usually turns into an ulcer. Yeah, it’s never just 
appeared for no reason, it’s always been a cut, you know
Poor circulation 4 P8 L2: For me it’s lack of blood, lack of blood
Calcinosis 5 P2 M1: The calcium seems to come white, the calcium and then it gets infected 




Effect of previous 
ulcers
6 P4 B1: the ulcers are only breaking open where I’ve had previous damage, 
obviously the fingers are compromised
7 P5 M2: it just looks like a, it starts off with a very, very uncomfortable kind of 
hypersensitivity where again you think, oh it’s going to come and you see 
like a little black dot and you think I’ve no idea what this is, but then it, it 
builds into what looks like an abscess maybe under your nail
Pain and 
pressure
8 P6 B1: I’ve definitely had sort of a feeling and with nothing there, that 
something’s going to happen. And then it’ll get really sore and it, with me, 
it just sort of broke into a yellow gungy mess
9 P5 L1: Yeah, for me I get that kind of, like, it kind of looks, looks like a whitish, 
but it’s not a full on ulcer yet. … I think they have their own life, once 
you’ve got one coming it’s going to come and live out its life before it goes
Symptoms 
prior to DU 
emergence
Physical changes
10 P7 L2: it’s almost like a weird infection, it starts off dry and I think it works its 
way in, in to the finger more and more, it feels like it’s touching the nerve 
and it’s like the…whole thing opens up
11 P4 B1: It goes into like a white spot and then that will break down and then that 
will weep
12 P7 B1: Normally the skin of whichever finger’s affected will harden. And that will 
almost turn into like a big kind of scab, or core if you like, and if that core 
is knocked out or removed in anyway shape, or form then it’s properly 
painful and if you just touch it on anything it’s agonising
13 P5 L1: I find, you know when that scab comes off underneath it is quite, it can be 








14 P1 L1 They kind of scab eventually don’t they? They start off moist and then 
become a scab and dry up.”
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